Fig. 2From: Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiencyEstablishment of the maximum tolerated dose for N-acetylcysteine in adults with chronic kidney disease. Four hundred and fifty mg/kg N-acetylcysteine was found to be the maximum tolerated dose in both intravenous and intra-arterial groups. Asterisk: Adverse reaction to contrast agent rather than to N-acetylcysteine. IV intravenous, IA intra-arterial, MTD maximum tolerated doseBack to article page